Takeda Pharmaceuticals has struck a $2 billion deal with AC Immune to develop an Alzheimer's vaccine. AC Immune is set to provide efficacy data after a mid-stage trial within the next 12 months. Takeda aims to bolster its clinical pipeline with this agreement.
Interesting announcement, @TakedaPharma signed an agreement with @AC_Immune_SA for AC's Immune’s anti-Abeta active immunotherapy candidate. Could lead to active immunotherapy targeting Amyloid Beta for Alzheimer’s Disease #BrainHealth https://t.co/6NwXG32JXD
Immunotherapy has become a key treatment option for cancer. Can it also treat Alzheimer's? Takeda is betting $100M on an AC Immune therapy to reduce amyloid plaque. Check out the full story: https://t.co/DIo2a9Jnt3 #Alzheimers #immunotherapy https://t.co/6mnavFCVGI
Takeda Pharmaceuticals reaches $2bn deal to develop Alzheimer’s vaccine https://t.co/4gbeANDgRN
.@TakedaPharma lost an #Alzheimers drug prospect last year. Disappointing Phase 1 data led Takeda and partner Denali Therapeutics to discontinue a brain-penetrating antibody drug. Takeda now gets another chance in Alzheimer’s with @AC_Immune_SA. https://t.co/wqzeWtOZ1i $ACIU $TAK
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune https://t.co/p7k3kvaNTS $TAK $ACIU by @realJacobBell
Takeda Pharmaceutical has secured an option on an Alzheimer’s disease immunotherapy from AC Immune that is on track to report its first Phase 2 data later this quarter. Exercising the option would make Takeda responsible for Phase 3 testing of the... https://t.co/Pjl21MHELd
Takeda nabs option to license #Alzheimers immunotherapies from AC Immune https://t.co/lthrM6ONoA by @realJacobBell $TAK $ACIU + 35%
. @TakedaPharma has made a strong play for a stake in the #Alzheimers disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy. $TAK $ACIU https://t.co/Tw1LVkRjtj https://t.co/sD6gM95qjJ
Takeda Signs Deal Worth $2.2 Billion with AC Immune for Alzheimer’s Vaccine AC Immune has signed a major deal with Japanese big pharma Takeda with a view to getting its amyloid-beta Alzheimer's vaccine to the market. Read more: https://t.co/FHLrifSJL0 https://t.co/1XCJ5RBx2z
Japan's Takeda reaches $2bn deal to develop potential Alzheimer's vaccine https://t.co/rSVtOzdj7M
Takeda may be paring back its R&D pipeline, but that hasn't stopped the Japanese pharma from doling out $100 million to ensure its clinical pipeline once again features an Alzheimer’s disease drug. https://t.co/4TxvfBs93E
Takeda Pharmaceuticals reaches $2bn deal to develop Alzheimer’s vaccine https://t.co/AsAzHMbG6E via @ft
$ACIU (+51.1% pre) AC Immune SA (ACIU) and Takeda $TAK Enter Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease - SI https://t.co/hnWil46d7N
Takeda Pharmaceuticals reaches $2bn deal to develop Alzheimer’s vaccine: “AC Immune would not have efficacy data for the drug until it completed a mid-stage trial within the next 12 months.” https://t.co/1qgwQorARd